These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Successful chemoimmunotherapy of murine L1210 lymphatic leukemia with cyclophosphamide and mafosfamide-treated leukemia cells.
    Author: Kawalec M, Skórski T, Kawiak J.
    Journal: Invest New Drugs; 1988 Sep; 6(3):169-72. PubMed ID: 3192382.
    Abstract:
    Balb/c x DBA/2 F1 mice (CD2F1 mice) bearing L1210 lymphatic (10 L1210 cells i.p. injected on day 0) were subjected to chemoimmunotherapy. They received 100 mg/kg of cyclophosphamide i.p. on day +8 and 10(6) or 10(7) immunogenic L1210 cells treated in vitro with mafosfamide - ASTA Z7654 (L1210-Maf cells) i.p. or i.p. + s.c. on days 0, +3, +6, +9, +12 after the leukemia implantation. About 30% of leukemia-bearing mice receiving cyclophosphamide and L1210-Maf cells after L1210 inoculation were able to reject the leukemia (as compared with 0% after injection of L1210-Maf cells only or 5% after cyclophosphamide administration). Better results (54% of cured mice) were obtained if 10(7) L1210-Maf cells were injected i.p. +s.c. beside cyclophosphamide. Biological response modifiers (BRM's): levamisole, BCG, bestatin did not improve these results in the doses used in the experiment. Augmentation of anti-L1210 therapeutic response is dependent on the administration of cyclophosphamide and L1210-Maf cels. Cyclophosphamide not only reduces the tumor burden but probably can potentiate the L1210-Maf dependent antitumor immunity as well.
    [Abstract] [Full Text] [Related] [New Search]